Drugs Index
Medical Conditions:
- Medical Conditions G
- Medical Conditions I
- Medical Conditions P
- Medical Conditions C
- Medical Conditions N
- Medical Conditions T
- Medical Conditions E
- Medical Conditions D
- Medical Conditions F
- Medical Conditions H
- Medical Conditions M
- Medical Conditions B
- Medical Conditions U
- Medical Conditions O
- Medical Conditions S
- Medical Conditions A
- Medical Conditions R
- Medical Conditions L
- Medical Conditions W
- Medical Conditions V
- Medical Conditions K
- Medical Conditions J
- Medical Conditions X
Drug Classes
- Drug Classes A
- Drug Classes M
- Drug Classes H
- Drug Classes C
- Drug Classes B
- Drug Classes U
- Drug Classes T
- Drug Classes O
- Drug Classes I
- Drug Classes N
- Drug Classes V
- Drug Classes E
- Drug Classes G
- Drug Classes P
- Drug Classes L
- Drug Classes Q
- Drug Classes F
- Drug Classes S
- Drug Classes D
- Drug Classes R
- Drug Classes 5
- Drug Classes K
Drugs Information:
Drugs List
1. Name Of The Medicinal Product
FASIGYN
2. Qualitative And Quantitative Composition
Tinidazole 500mg
3. Pharmaceutical Form
Film-coated tablets
White, round, biconvex film-coated tablet embossed on one side with “FAS 500”
4. Clinical Particulars
4.1 Therapeutic Indications
Treatment of the following infections:
• Eradication of Helicobacter pylori associated with duodenal ulcers, in the presence of antibiotic and acid suppressant therapy. (See 'Posology and method of administration'.)
• Anaerobic infections such as:
Intraperitoneal infections: peritonitis, abscess.
Gynaecological infections: endometritis, endomyometritis, tube-ovarian abscess.
Bacterial septicaemia.
Post-operative wound infections.
Skin and soft tissue infections.
Upper and lower respiratory tract infections: pneumonia, empyema, lung abscess.
• Non-specific vaginitis.
• Acute ulcerative gingivitis.
• Urogenital trichomoniasis in both male and female patients.
• Giardiasis.
• Intestinal amoebiasis.
• Amoebic involvement of the liver.
Prophylaxis
The prevention of post-operative infections caused by anaerobic bacteria, especially those associated with colonic, gastro-intestinal and gynaecological surgery.
4.2 Posology And Method Of Administration
Oral administration during or after a meal.
•Eradication of H.pylori associated with duodenal ulcers
1. Name Of The Medicinal Product
Fucidin® H Ointment
2. Qualitative And Quantitative Composition
Fucidin® H Ointment contains Sodium Fusidate Ph. Eur. 2% and Hydrocortisone Acetate Ph.Eur. 1%.
3. Pharmaceutical Form
Ointment for topical administration.
4. Clinical Particulars
4.1 Therapeutic Indications
Fucidin® H Ointment is indicated in eczema and dermatitis with secondary bacterial infections, including atopic eczema, primary irritant dermatitis and allergic and seborrhoeic dermatitis where the organisms responsible are known to be or believed to be sensitive to fusidic acid.
4.2 Posology And Method Of Administration
Adults and Children: Uncovered lesions – a small quantity should be applied to the affected area twice daily until a satisfactory response is obtained. A single treatment course should not normally exceed 2 weeks.
Covered lesions - less frequent applications may be adequate.
4.3 Contraindications
Hypersensitivity to fusidic acid and its salts. As with other topical corticosteroid preparations, Fucidin® H Ointment is contra-indicated in primary bacterial, viral and fungal skin infections, skin manifestations in relation to tuberculosis or syphilis, perioral dermatitis and rosacea.
4.4 Special Warnings And Precautions For Use
Fucidin® H Ointment should not be used in or near the eye as sodium fusidate causes conjunctival irritation.
Bacterial resistance has been reported to occur with the use of fusidic acid applied topically. As with all topical antibiotics, extended or recurrent application may increase the risk of contact sensitisation and the development of antibiotic res
1. Name Of The Medicinal Product
FELDENE™ 10mg CAPSULES.
FELDENE™ 20mg CAPSULES.
FELDENE™ 20mg/ml INTRAMUSCULAR INJECTION.
Feldene™ Melt 20mg.
2. Qualitative And Quantitative Composition
Active Ingredient: piroxicam.
Capsules: piroxicam 10mg or 20mg (anhydrous).
I.M.: the intramuscular injection contains 1ml of piroxicam solution (20mg/ml) in ampoules of 1ml.
Melt tablets: piroxicam 20mg.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Capsules (10mg and 20mg): Capsules for oral administration.
I.M.: Solution for intramuscular injection.
Melt tablets: Fast Dissolving Dosage Form (Tablet).
4. Clinical Particulars
4.1 Therapeutic Indications
Capsules, Melt tablets, IM: Feldene is indicated for symptomatic relief of osteo-arthritis, rheumatoid arthritis or ankylosing spondylitis.
Due to its safety profile (see sections 4.2, 4.3 and 4.4), Feldene is not a first line option should an NSAID be indicated. The decision to prescribe Feldene should be based on an assessment of the individual patient's overall risks (see sections 4.3 and 4.4).
4.2 Posology And Method Of Administration
IM only: Feldene I.M. is for intramuscular administration only.
The prescription of Feldene should be initiated by physicians with experience in the diagnostic evaluation and treatment of patients with inflammatory or degenerative rheumatic diseases.
The maximum recommended daily dose is 20 mg.
Undesirable effects may be minimised by using the minimum effective dose for the shortest
Foscavir
What you should know about Foscavir
foscarnet
Please read this carefully before you take your medicine. It is designed to help you understand more about Foscavir. If you have any questions or feel unsure about anything, ask your doctor or pharmacist (chemist).
What is in Foscavir?
Each ml of solution contains 24 mg of the active ingredient, foscarnet trisodium hexahydrate in water. The product also contains sufficient hydrochloric acid to adjust the acidity of the solution to be similar to the blood.
Foscavir is a sterile solution for injection into a vein. It comes in bottles containing 250 ml.
Who has made Foscavir?
The Marketing Authorisation for Foscavir is held by
Foscavir is manufactured by
What is Foscavir used for?
The active ingredient in Foscavir – foscarnet – is an antiviral agent and works by preventing some viruses from multiplying. Foscavir is used in the treatment of a viral eye infection (retinitis) caused by cytomegalovirus (CMV) in patients with AIDS. Foscavir prevents the condition from getting worse but cannot repair the
1. Name Of The Medicinal Product
Finasteride 5mg film-coated tablets
2. Qualitative And Quantitative Composition
One film-coated tablet contains 5mg finasteride
Excipient: lactose monohydrate (97.5mg)
For a full list of excipients, see section 6.1
3. Pharmaceutical Form
Film-coated tablet
Blue coloured, circular, biconvex, beveled edged film-coated tablets debossed with 'E' on one side and '61' on the other side.
4. Clinical Particulars
4.1 Therapeutic Indications
Finasteride 5mg is indicated for the treatment and control of benign prostatic hyperplasia (BPH) to:
- cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH
- reduce the incidence of acute urinary retention and reduce need for surgery including transurethral resection of the prostate (TURP) and prostatectomy
Finasteride should be administered in patients with an enlarged prostate (prostate volume above ca. 40ml).
4.2 Posology And Method Of Administration
Finasteride is for oral use only.
Dosage in adults
The recommended dosage is one 5mg tablet daily with or without food. The tablet should be swallowed whole and must not be divided or crushed (see section 6.6).
Even though improvement can be seen within a short time, treatment for at least 6 months may be necessary in order to determine objectively whether a satisfactory response to treatment has been achieved.
Dosage in the elderly
Dosage adjustments are not necessary although pharmacokinetic studies have shown that the elimination rate of finaster
1. Name Of The Medicinal Product
Fluorouracil Injection 25 mg/ml, solution for injection
2. Qualitative And Quantitative Composition
One vial of Fluorouracil Injection contains:
2500 mg fluorouracil in 100 ml solution (25 mg/ml)
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Solution for injection
Fluorouracil Injection 25 mg/ml, solution for injection, is a clear, colourless or almost colourless solution.
4. Clinical Particulars
4.1 Therapeutic Indications
Fluorouracil Injection 25 mg/ml, solution for injection, may be used alone or in combination, for its palliative action in the management of common malignancies particularly cancer of the colon and breast, either as single agent or in combination with other cytotoxic agents.
4.2 Posology And Method Of Administration
Routes of administration:
Fluorouracil Injection can be given by intravenous injection or intravenous or intra-arterial infusion.
Adults:
Selection of an appropriate dose and treatment regime depends upon the condition of the patient, the type of carcinoma being treated and whether fluorouracil is to be administered alone or in combination with other therapy. Initial treatment should be given in hospital and the total daily dose should not exceed 0.8 – 1 gram. It is customary to calculate the dose in accordance with the patient's actual bodyweight unless there is obesity, oedema or some other form of abnormal fluid retention such as ascites. In this case, ideal weight is used as the basis for calculation.
Reduction of the dose is advisable in patients with any of the following:
Fucibet Cream
fusidic acid and betamethasone valerate
Please read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects become serious, or you notice any side effects not listed in this leaflet please tell you doctor or pharmacist.
- In this leaflet Fucibet Cream will be called Fucibet.
In this leaflet:
- 1. What Fucibet is and what it is used for
- 2. Before you use Fucibet
- 3. How to use Fucibet
- 4. Possible side effects
- 5. How to store Fucibet
- 6. Further information
What Fucibet Is And What It Is Used For
Fucibet contains two different types of medicine. One medicine is called fusidic acid. It is a type of antibiotic.
The other medicine is called betamethasone valerate. It is a type of corticosteroid (steroid). These two medicines work at the same time in different ways.
Fucibet works by:
- The antibiotic killing germs (bacteria) that cause infections.
- The corticosteroid reducing any swelling, redness or itchiness of your skin.
Fucibet is us
1. Name Of The Medicinal Product
1. Fragmin 10,000 IU/1 ml
2. Fragmin 10,000 IU/4ml
2. Qualitative And Quantitative Composition
Active ingredient
Dalteparin sodium (INN)
Quality according to Ph Eur and in-house specification.
Potency is described in International anti-Factor Xa units (IU) of the 1st International Standard for Low Molecular Weight Heparin.
Content of active ingredient
1. Ampoules containing dalteparin sodium, 10,000 IU (anti-Factor Xa) in 1 ml.
2. Fragmin 10,000 IU/4ml: Ampoules containing dalteparin sodium corresponding to 2,500 IU (anti-Factor Xa)/ml.
3. Pharmaceutical Form
Solution for injection for intravenous or subcutaneous administration.
4. Clinical Particulars
4.1 Therapeutic Indications
Prevention of clotting in the extracorporeal circulation during haemodialysis or haemofiltration, in patients with chronic renal insufficiency or acute renal failure.
4.2 Posology And Method Of Administration
Recommended dosage for adults
(i) Prevention of clotting during haemodialysis and haemofiltration
In chronic renal insufficiency for patients with no known additional bleeding risk, the dosage is:
(a) Long-term haemodialysis or haemofiltration - duration of haemodialysis/haemofiltration more than 4 hours;
An I.V. bolus injection of Fragmin 30-40 IU (anti-Factor Xa)/kg bodyweight, followed by an infusion of 10-15 IU (anti-Factor Xa)/kg bodyweight/hour.
(b) Short-term haemodialysis or haemofiltration - durat
1. Name Of The Medicinal Product
FELDENE GEL
FELDENE SPORTS GEL
FELDENE GEL STARTER PACK.
2. Qualitative And Quantitative Composition
Active ingredient: Piroxicam
The Gel contains 5mg piroxicam in each gram in tubes of 7.5g - Feldene Gel starter Pack, 30g - Feldene Sports Gel, 60g and 112g - Feldene Gel.
3. Pharmaceutical Form
Gel for topical application.
4. Clinical Particulars
4.1 Therapeutic Indications
Feldene Gel is a non-steroidal anti-inflammatory agent indicated for a variety of conditions characterised by pain and inflammation, or stiffness. It is effective in the treatment of osteoarthritis of superficial joints such as the knee, acute musculoskeletal injuries, periarthritis, epicondylitis, tendinitis, and tenosynovitis.
4.2 Posology And Method Of Administration
Dosage
Adults Feldene Gel, Feldene Sports Gel and Feldene Gel Starter Pack are for external use only. No occlusive dressings should be employed. Apply 1g of Gel, corresponding to 3cms, and rub into the affected site three to four times daily leaving no residual material on the skin. Therapy should be reviewed after 4 weeks.
Use in Children (See under 'Special warnings and special precautions for use').
Use in the Elderly (See under 'Special warnings and special precautions for use').
4.3 Contraindications
Feldene Gel, Feldene Sports Gel and Feldene Gel Starter Pack should not be used in those patients who have previously shown a hypersensitivity to the Gel or piroxicam in any of its forms. The potential exists for cross sensitivity to aspir
1. Name Of The Medicinal Product
Fybogel Orange.
2. Qualitative And Quantitative Composition
A unit dose (one sachet or two level 5 ml spoonfuls) contains 3.5 g ispaghula husk BP.
3. Pharmaceutical Form
Effervescent granules.
4. Clinical Particulars
4.1 Therapeutic Indications
The treatment of patients requiring a high fibre regime: for example, for the relief of constipation, including constipation in pregnancy and the maintenance of regularity; for the management of bowel function in patients with colostomy, ileostomy, haemorrhoids, anal fissure, chronic diarrhoea associated with diverticular disease, irritable bowel syndrome and ulcerative colitis.
4.2 Posology And Method Of Administration
Fybogel Orange is intended for oral use as a suspension in a drink of water. The granules should be stirred into a glass of water and taken as soon as the effervescence subsides, preferably after meals.
|
Adults and children over 12 years: |
One sachet or two level 5ml spoonfuls morning and evening. |
|
Elderly: |
There is no indication that dosage needs to be modified for the elderly. |
|
Children aged 6 to 12 years: |
Half to one level 5 ml spoonful, depending on age and size, morning and evening. |
1. Name Of The Medicinal Product
Femoston-conti ® 1 mg/5 mg film-coated tablets
2. Qualitative And Quantitative Composition
Each film-coated tablet contains 1 mg estradiol as estradiol hemihydrate and 5 mg dydrogesterone.
Excipient(s): Lactose
For a full list of excipients, see 6.1.
3. Pharmaceutical Form
Film-coated “tablet”.
Salmon-coloured, round, biconvex, film-coated “tablet” imprinted '
4. Clinical Particulars
4.1 Therapeutic Indications
Hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women. Femoston-conti should be used only in postmenopausal women more than 12 months after menopause.
Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
(See also section ?4.4)
The experience in treating women older than 65 years is limited.
4.2 Posology And Method Of Administration
Femoston-conti is a continuous combined HRT.
The dosage is one tablet per day. Femoston-conti should be taken continuously without a break between packs.
Femoston-conti can be taken with or without food.
Starting Femoston-conti:
Women experiencing a natural menopause should commence treatment with Femoston-conti 12 months after their last natural menstrual bleed. For surgically induced menopause, treatment may start immediately.
In women who are not taking hormone replacement therapy or women, who switch from a continuous combined hormone replacement therapy, treatment may be started
1. Name Of The Medicinal Product
FORAVEN XL 75mg modified release capsules
2. Qualitative And Quantitative Composition
FORAVEN XL 75mg modified release capsules contain 84.8mg of venlafaxine hydrochloride, equivalent to 75mg of venlafaxine free base, in an extended release formulation.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Modified release capsules, hard. The capsules are opaque peach having a thick and a thin radial circular band on the body in red ink and a thick and a thin radial circular band on the cap in red ink.
4. Clinical Particulars
4.1 Therapeutic Indications
Major depressive disorder
FORAVEN XL 75mg modified release capsules are indicated for the treatment of major depressive disorder including depression accompanied by anxiety. All patients should be evaluated for the risk of suicidality and monitored for clinical worsening (see section 4.2 and 4.4).
Following an initial response venlafaxine capsules are indicated for the prevention of relapses of the initial episode of depression or for the prevention of the recurrence of new episodes.
4.2 Posology And Method Of Administration
Depression
The recommended dose is 75mg per day given once daily. Most patients respond to this dose.
If, after an adequate trial and evaluation, further clinical improvement is required, the dose may be increased to 150mg per day given once daily. There may be an increased risk of side effects at higher doses and dose increments should be made only after a clinical evaluation and after at least 3-4 weeks of therapy (see section 4.4). The lowest effective dose should be maintained.
1. Name Of The Medicinal Product
Flebogamma DIF 100 mg/ml
2. Qualitative And Quantitative Composition
Human normal immunoglobulin (IVIg)
One ml contains:
Human normal immunoglobulin 100 mg (purity of at least 97% IgG)
One vial of 50 ml contains: 5 g of human normal immunoglobulin
One vial of 100 ml contains: 10 g of human normal immunoglobulin
One vial of 200 ml contains: 20 g of human normal immunoglobulin
Distribution of the IgG subclasses (approx. values):
|
IgG1 |
66.6% |
|
IgG2 |
27.9% |
|
IgG3 |
3.0% |
|
IgG4 |
2.5% |
The maximum IgA content is 100 micrograms/ml.
Produced from the plasma of human donors.
Excipients:
One ml contains 50 mg of D-Sorbitol.
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Solution for infusion
The solution is clear or slightly opalescent and colourless or pale yellow.
Flebogamma DIF is isotoni
1. Name Of The Medicinal Product
Fematrix 80 Transdermal Patch
2. Qualitative And Quantitative Composition
Fematrix 80 contains 2.5 mg of estradiol and each patch delivers approximately 80 micrograms of estradiol per 24 hours.
For excipients, see 6.1
3. Pharmaceutical Form
Transdermal patch
Self adhesive, flexible transdermal patch comprising a layer of clear adhesive sandwiched between a translucent patch and a metallised polyester backing. Fematrix 80 is a rectangular shape with rounded corners and has an active surface area of 28.5 cm?.
4. Clinical Particulars
4.1 Therapeutic Indications
Hormone replacement therapy (HRT) for estrogen deficiency symptoms in peri and postmenopausal women.
Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
(See also section 4.4)
The experience treating women older than 65 years is limited.
4.2 Posology And Method Of Administration
Fematrix 80 is an estrogen-only continuous HRT for women with or without a uterus.
In women with a uterus, a progestagen such as Dydrogesterone 10mg, should be added to Fematrix 80 for 12-14 days each month to reduce the risk to the endometrium. Unless there is a previous diagnosis of endometriosis, it is not recommended to add a progestagen in hysterectomised women.
For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.
In general, treatment should start with Fematrix 40. Depending on the clinical r
FAMVIR 125, 250, 500 and 750 mg Tablets
(famciclovir)
What you need to know about Famvir Tablets
Your doctor has decided that you need this medicine to help treat your condition.
Please read this leaflet carefully before you start to take your medicine. It contains important information. Keep the leaflet in a safe place because you may want to read it again.
If you have any other questions, or if there is something you don’t understand, please ask your doctor or pharmacist.
This medicine has been prescribed for you. Never give it to someone else. It may not be the right medicine for them even if their symptoms seem to be the same as yours.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
- 1. What Famvir Tablets are, and what they are used for
- 2. Things to consider before you start to take Famvir Tablets
- 3. How to take Famvir Tablets
- 4. Possible side effects
- 5. How to store Famvir Tablets
- 6. Further information
What Famvir Tablets Are And What They Are Used For
Famciclovir, the active ingredient in Famvir Tablets, is an antiviral medicine. It stops some Herpes viruses multiplying and spreading within your body.
Famvir Tablets are used to treat attacks of Herpes zoster infections (shingles) or Herpes simplex infections (genital herpes). They are available in four different strengths.
Things T
1. Name Of The Medicinal Product
Folic Acid 2.5mg/5ml Oral Solution
2. Qualitative And Quantitative Composition
Folic Acid 2.5mg/5ml
Excipients:
Methyl hydroxybenzoate (E218)
Ethyl hydroxybenzoate (E214)
Propyl hydroxybenzoate (E216)
Phenylalanine
For full list of excipients, see section 6.1.
3. Pharmaceutical Form
Oral Solution.
A clear, yellow, solution with a strawberry flavour and odour.
4. Clinical Particulars
4.1 Therapeutic Indications
1. Folate deficient megaloblastic anaemia
2. Folate deficient megaloblastic anaemia in infants
3. Treatment of folate deficiency in malabsorption syndromes (parenteral administration of folic acid may need to be considered if oral treatment is not effective)
|
3.1 Tropical sprue. Tropical sprue responds to folate supplements in the early stages of the disease but cobalamin status must also be checked, particularly later. |
|
|
3.2 Coeliac disease. The necessity of supplementation with folate ceases once a gluten free diet is introduced. |
|
|
3.3 Non-tropical sprue. In congenital folate malabsorption, oral treatment may not be effective and parental folate may therefore be required. |
1. Name Of The Medicinal Product
FAMVIR® 750 mg Tablets
2. Qualitative And Quantitative Composition
Famciclovir 750 mg
3. Pharmaceutical Form
White, oval, film-coated 'Tiltab' tablets containing 750 mg famciclovir for oral administration.
4. Clinical Particulars
4.1 Therapeutic Indications
For the treatment of herpes zoster (shingles) infections.
4.2 Posology And Method Of Administration
Dosage:
Adults:
Herpes Zoster Infections
One 750 mg tablet once daily for seven days. The tablet should be taken at approximately the same time each day. Treatment should be initiated as early as possible in the course of the disease, promptly after diagnosis.
Elderly:
Dosage modification is not required unless renal function is impaired.
Renally Impaired:
As reduced clearance of penciclovir is related to reduced renal function, special attention should be given to dosage in patients with impaired renal function. The following modifications are recommended:
For the treatment of herpes zoster infections:
|
Creatinine clearance (ml/min/1.73m2 ) |
Dosage |
|
30-59 |
1. Name Of The Medicinal Product
Fortral Injection 30 mg / ml
2. Qualitative And Quantitative Composition
Each 1 ml ampoule contains 30 mg pentazocine (as lactate).
Each 2 ml ampoule contains 60 mg pentazocine (as lactate).
3. Pharmaceutical Form
Solution for injection.
4. Clinical Particulars
4.1 Therapeutic Indications
Fortral is a strong analgesic for the relief of moderate to severe pain.
4.2 Posology And Method Of Administration
Adults
Fortral Injections may be administered subcutaneously, intramuscularly or intravenously. The usual starting dose is 30mg to 60mg according to the severity. The dose should be adjusted according to response and repeated as necessary every three to four hours. A dose should not normally exceed 1mg/kg body weight SC or IM, or 0.5mg/kg iv.
The maximum daily dose is 360mg.
Children
In the case of patients between 1 year and 12 years, the maximum single dose of parenteral Fortral should be calculated on the basis of 1mg/kg body weight intravenously.
Fortral Injection is not recommended for use in children under one year.
Elderly
Since impaired renal or hepatic function is often associated with ageing, elderly patients may require smaller doses of Fortral.
4.3 Contraindications
Fortral should not be administered to patients with established respiratory depression especially in the presence of cyanosis and excessive bronchial secretion and is also contraindicated in the presence of acute alcoholism, head injuries, conditions in which intracranial
Fluvastatin 20mg and 40mg capsules
Read all of this leaflet carefully before you start taking this medicine
- Keep this leaflet. You may need to read it again.
- If you have any further questions, please ask your doctor or pharmacist.
- Fluvastatin capsules has been prescribed for you. Do not pass Fluvastatin on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist.
In this leaflet:
- 1. What Fluvastatin is and what it is used for
- 2. Before you take
- 3. How to take
- 4. Possible side effects
- 5. How to store
- 6. Further information
What Fluvastatin Is And What It Is Used For
Fluvastatin belongs to a group of medicines that lowers the levels of cholesterol and triglycerides in the blood. Cholesterol and triglycerides are fats (lipids) in the blood, which in high concentrations can damage the blood vessels. The fats are deposited on the walls of the blood vessels narrowing the vessels and making them less elastic (coronary arteriosclerosis). This increases the risk of heart-attacks and strokes.
Fluvastatin is used when a dietetic treatment only is insufficient for lowering the level of cholesterol in the blood. Fluvastatin is used in patients with coronary arteriosclerosis and too high level of cholesterol in the blood to prevent further serious cardiac events (e.g. heart attack), after heart catheterization
Floxapen 250mg and 500mg capsules
(flucloxacillin)
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others.
It may harm them, even if their symptoms are the same as yours.
Index
- 1 What Floxapen capsules are and what they are used for
- 2 Before you take
- 3 How to take
- 4 Possible side effects
- 5 How to store
- 6 Further information
What Floxapen capsules are and what they are used for
Flucloxacillin is an antibiotic used to treat infections by killing the bacteria that can cause them. It belongs to a group of antibiotics called “penicillins”.
Floxapen capsules are used to treat:
- chest infections
- throat or nose infections
- ear infections
- skin and soft tissue infections
- heart infections
- bones and joints infections
- meningitis
- digestive system infections
- blood infections
- kidney, bladder or urethra (the tube which carries urine from the bladder)